The global lipase market is anticipated to reach USD 279.6 million by 2025 and is projected to grow at a robust CAGR of 10.3% ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently approved OCREVUS IV 600 ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III MUSETTE trial comparing a high dose of Ocrevus® (ocrelizumab) intravenous (IV) infusion to the ...

Asafoetida is a powerful herb with numerous benefits, including promoting digestive health, supporting women’s well-being, ...